Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HPT014
MIFTS: 49

Hepatorenal Syndrome

Categories: Gastrointestinal diseases, Liver diseases, Nephrological diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hepatorenal Syndrome

About this section

MalaCards integrated aliases for Hepatorenal Syndrome:

Name: Hepatorenal Syndrome 12 77 54 56 45 15 74
Hepato-Renal Syndrome 54

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Gastrointestinal diseases Nephrological diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:11823
ICD9CM 36 572.4
MeSH 45 D006530
NCIt 51 C113400
SNOMED-CT 69 51292008
ICD10 34 K76.7
UMLS 74 C0019212
Sources

Summaries for Hepatorenal Syndrome

About this section
NIH Rare Diseases : 54 Hepatorenal syndrome is a form of impaired kidney function that occurs in individuals with advanced chronic liver disease. As many as 40% of individuals with cirrhosis and ascites will develop hepatorenal syndrome. Symptoms may include fatigue, abdominal pain, and a general feeling of ill health (malaise). There are two distinct types of hepatorenal syndrome. Type I progresses quickly (within days), leading to kidney failure. Individuals with type I typically have dramatically reduced urine output, edema, and jaundice, and often suffer from hepatic encephalopathy. Type II progresses more slowly, over weeks or months, and the symptoms are less severe. The cause of hepatorenal syndrome is unknown. A contributing factor seems to be a narrowing of the blood vessels that connect into the kidneys. This causes a decrease in blood flow to the kidneys, impairing their function. In some cases, triggers or precipitating factors (infections, blood loss from the gastrointestinal tract, low blood pressure) are involved. Treatment is aimed at helping the liver work better and maintaining kidney function. In many cases, a liver transplant is needed. In some cases, individuals also need a kidney transplant. 

MalaCards based summary : Hepatorenal Syndrome, also known as hepato-renal syndrome, is related to infantile liver failure syndrome 1 and acute liver failure. An important gene associated with Hepatorenal Syndrome is ALB (Albumin), and among its related pathways/superpathways are FOXA2 and FOXA3 transcription factor networks and Endothelin Pathways. The drugs Terlipressin and Telbivudine have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and heart, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 An acute kidney failure that is characterized by severe renal vasoconstriction.

Wikipedia : 77 Hepatorenal syndrome (often abbreviated HRS) is a life-threatening medical condition that consists of... more...

Sources

Related Diseases for Hepatorenal Syndrome

About this section

Diseases related to Hepatorenal Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
# Related Disease Score Top Affiliating Genes
1 infantile liver failure syndrome 1 30.9 ALB F2
2 acute liver failure 30.3 ALB F2
3 hepatic coma 30.2 ALB F2
4 esophageal varix 30.2 ALB F2
5 compartment syndrome 30.2 ALB F2
6 hepatopulmonary syndrome 30.0 ALB EDN1
7 portal hypertension 29.9 ALB EDN1 F2
8 obstructive jaundice 29.9 ALB EDN1 F2 REN
9 acute kidney tubular necrosis 29.9 ALB CST3 IL18 NPPA
10 liver cirrhosis 29.8 ALB AQP2 EDN1 F2 NPPA REN
11 hepatitis a 29.8 ALB F2
12 eclampsia 29.7 ALB EDN1 F2 REN
13 pre-eclampsia 29.5 EDN1 F2 NPPA REN
14 pulmonary hypertension 29.1 ACE EDN1 NPPA REN
15 pulmonary edema 28.8 ACE EDN1 F2 NPPA REN
16 kidney disease 28.0 ACE ALB AQP2 CST3 EDN1 NPPA
17 joubert syndrome with oculorenal anomalies 11.7
18 peroxisome biogenesis disorder 1a 11.3
19 benign essential hypertension 10.4 ALB REN
20 kidney papillary necrosis 10.4 ALB REN
21 liver disease 10.4
22 antipyrine metabolism 10.4 ALB F2
23 non-a-e hepatitis 10.4 ALB F2
24 malignant hypertensive renal disease 10.4 EDN1 REN
25 malignant renovascular hypertension 10.4 EDN1 REN
26 epstein-barr virus hepatitis 10.3 ALB F2
27 malignant secondary hypertension 10.3 EDN1 REN
28 fournier gangrene 10.3 ALB F2
29 perinephritis 10.3 EDN1 REN
30 abdominal tuberculosis 10.3 ALB F2
31 intestinal impaction 10.3 F2 REN
32 hepatic tuberculosis 10.3 ALB F2
33 kwashiorkor 10.3 ALB F2
34 hepatitis 10.3
35 noma 10.3 ALB IL18
36 splenic disease 10.3 ALB F2
37 ascending cholangitis 10.3 ALB F2
38 cardiac tamponade 10.3 F2 REN
39 renal tuberculosis 10.3 EDN1 REN
40 hypersplenism 10.3 ALB F2
41 choledocholithiasis 10.3 ALB F2
42 analbuminemia 10.3 ALB F2
43 autoimmune disease of urogenital tract 10.3 ALB F2
44 pulmonary artery disease 10.3 ALB F2
45 dysfibrinogenemia 10.3 ALB F2
46 apnea, obstructive sleep 10.3 EDN1 REN
47 acute cystitis 10.2 ALB IL18
48 autonomic nervous system disease 10.2 ALB NPY
49 acute poststreptococcal glomerulonephritis 10.2 EDN1 NPPA
50 hepatitis e 10.2 ALB F2

Comorbidity relations with Hepatorenal Syndrome via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alcoholic Liver Cirrhosis
Chronic Kidney Failure Deficiency Anemia
Heart Disease Hepatic Encephalopathy
Portal Hypertension

Graphical network of the top 20 diseases related to Hepatorenal Syndrome:



Diseases related to Hepatorenal Syndrome
Sources

Symptoms & Phenotypes for Hepatorenal Syndrome

About this section

MGI Mouse Phenotypes related to Hepatorenal Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.96 ACE ALB AQP2 CST3 EDN1 F2
2 cardiovascular system MP:0005385 9.91 ACE CST3 EDN1 F2 IL18 NPPA
3 mortality/aging MP:0010768 9.76 ACE ALB AQP2 CST3 EDN1 F2
4 digestive/alimentary MP:0005381 9.72 ALB EDN1 F2 IL18 NPY
5 muscle MP:0005369 9.43 ALB CST3 EDN1 IL18 NPPA REN
6 renal/urinary system MP:0005367 9.17 ACE ALB AQP2 EDN1 NPPA NPY
Sources

Drugs & Therapeutics for Hepatorenal Syndrome

About this section

Drugs for Hepatorenal Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 14636-12-5 72081
2
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
3
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
4
Norfloxacin Approved Phase 4 70458-96-7 4539
5
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
6
Mannitol Approved, Investigational Phase 4,Phase 3 69-65-8 6251 453
7
Tranexamic Acid Approved Phase 4 1197-18-8 5526
8
Isoleucine Approved, Investigational, Nutraceutical Phase 4 73-32-5, 443-79-8 6306
9
Adefovir Investigational Phase 4 106941-25-7
10 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Vasoconstrictor Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
12 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Nucleic Acid Synthesis Inhibitors Phase 4
14 Anti-Retroviral Agents Phase 4
15 Antiviral Agents Phase 4,Phase 2,Not Applicable
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Reverse Transcriptase Inhibitors Phase 4
18 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Not Applicable
19 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Not Applicable
20 Topoisomerase Inhibitors Phase 4
21 Cytochrome P-450 Enzyme Inhibitors Phase 4
22 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
23 Antifibrinolytic Agents Phase 4
24 Coagulants Phase 4
25 Hemostatics Phase 4,Not Applicable
26 leucine Phase 4
27 valine Phase 4
28 Anticoagulants Phase 4,Not Applicable
29 Blood Substitutes Phase 4
30 Plasma Substitutes Phase 4
31 Dextrans Phase 4
32
Pentoxifylline Approved, Investigational Phase 3,Not Applicable 6493-05-6 4740
33
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Not Applicable 302-25-0
34
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
35
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Not Applicable 2921-57-5
36
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741
37
Propranolol Approved, Investigational Phase 3,Not Applicable 525-66-6 4946
38
Octreotide Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 83150-76-9 6400441 383414
39
Midodrine Approved Phase 2, Phase 3,Phase 3,Not Applicable 133163-28-7, 42794-76-3 4195
40
Rifaximin Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 80621-81-4 46783403 6436173
41
Norepinephrine Approved Phase 3,Phase 2,Early Phase 1,Not Applicable 51-41-2 439260
42
Dopamine Approved Phase 2, Phase 3 62-31-7, 51-61-6 681
43
Tolvaptan Approved Phase 2, Phase 3 150683-30-0 216237
44
Spironolactone Approved Phase 2, Phase 3 1952-01-7, 52-01-7 5833
45
Furosemide Approved, Vet_approved Phase 2, Phase 3 54-31-9 3440
46
Sargramostim Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 123774-72-1, 83869-56-1
47
Lenograstim Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 135968-09-1
48
Mycophenolic acid Approved Phase 3 24280-93-1 446541
49
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
50
Sirolimus Approved, Investigational Phase 3 53123-88-9 46835353 5284616 6436030

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response Unknown status NCT01530711 Phase 4 Terlipressin and albumin
2 The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Unknown status NCT02489864 Phase 4 Terlipressin
3 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
4 Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis Completed NCT00359853 Phase 4 Oral norfloxacin
5 Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
6 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
7 Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
8 Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin Suspended NCT00287664 Phase 4 terlipressin
9 The INFECIR-2 Albumin Prevention Study Terminated NCT02034279 Phase 4 Albumin
10 Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis Terminated NCT00570960 Phase 4 Dextran 70
11 Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome Unknown status NCT00742690 Phase 2, Phase 3 terlipressin given by intravenous boluses and albumin;terlipressin given by continuous intravenous infusion and albumin
12 Short-term Survival in Patients With Severe Alcoholic Hepatitis Treated With Steroid Versus Pentoxifylline Unknown status NCT01455337 Phase 3 pentoxifylline;Prednisolone
13 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
14 Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1 Completed NCT00089570 Phase 3 terlipressin;Placebo
15 Noradrenalin vs Terlipressin in Hepatorenal Syndrome Completed NCT00370253 Phase 3 Terlipressin;Noradrenalin
16 A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin Completed NCT01143246 Phase 3 Terlipressin;Placebo
17 TYPE 2 HEPATORENAL SYNDROME Completed NCT01637454 Phase 3 Noradrenaline;Terlipressin
18 The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction Completed NCT00240045 Phase 2, Phase 3 Midodrine, albumin, octreotide LAR;midodrine, octreotide, albumin
19 Terlipressin in Septic Shock in Cirrhosis Completed NCT00628160 Phase 2, Phase 3 Terlipressin;alpha adrenergic drugs
20 Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites Completed NCT02173288 Phase 2, Phase 3 Standard medical therapy;Tolvaptan;Midodrine
21 Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. Completed NCT00502086 Phase 3
22 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Completed NCT02451033 Phase 2, Phase 3 standard medical therapy;G-CSF;Growth Hormone
23 CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment Completed NCT00604357 Phase 3 anti-CD 25 mAb, Sirolimus, MMF
24 Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis Completed NCT01214226 Phase 3 Pentoxifylline;placebo
25 Effects of Propofol on Oxidative Stress and Liver Regeneration After Partial Hepatectomy Completed NCT00219856 Phase 3 Propofol;Penthotal;Desflurane
26 Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1. Recruiting NCT03455322 Phase 2, Phase 3 norepinephrine versus midodrine & octreotide
27 Terlipressin Infusion Alone Vs Terlipressin With Noradrenaline Infusion In The Treatment of Hepatorenal Syndrome Type 1 Recruiting NCT03822091 Phase 3 Terlipressin;Terlipressin and Noradrenaline
28 Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction Recruiting NCT01453218 Phase 3 ATeGe-Fresenius
29 GCSF Therapy in Decompensated Cirrhosis - A Double Blinded RCT Recruiting NCT03911037 Phase 2, Phase 3 G-CSF;Placebo
30 Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone Recruiting NCT02281929 Phase 3 Amoxicillin;Placebo;Prednisolone
31 Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding Recruiting NCT01618890 Phase 3
32 Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites Recruiting NCT03069131 Phase 3 Rifaximin
33 Study To Confirm Efficacy and Safety of Terlipressin in HRS Type 1 Active, not recruiting NCT02770716 Phase 3 Terlipressin
34 Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome Terminated NCT00742339 Phase 2, Phase 3 Terlipressin plus albumin;Midodrine plus octreotide plus human albumin
35 Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE Withdrawn NCT00787436 Phase 3 Thalidomide
36 Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study Unknown status NCT00852800 Phase 2 Albumin;Albumin
37 Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis Unknown status NCT02116556 Phase 2 Prednisone;Rifaximin
38 UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver Failure Unknown status NCT02812121 Phase 2 umbilical cord blood mesenchymal stem cells
39 Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function Unknown status NCT00657306 Phase 2 hydrocortisone;dextrose solution 5%
40 Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Completed NCT01436500 Phase 2 Ifetroban Injection;Placebo
41 A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1 Completed NCT01373606 Phase 1, Phase 2 Terlipressin
42 Single Pass Albumin Dialysis in Patients With Cirrhosis Completed NCT00764049 Phase 1, Phase 2
43 A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis Completed NCT00562783 Phase 2 Vitaliver;Placebo
44 The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure Completed NCT01254994 Phase 2 entecavir;Traditional comprehensive medical treatment
45 Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment Completed NCT01133795 Phase 2 Midodrine plus Albumin
46 Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH) Completed NCT02854631 Phase 2 Selonsertib;Prednisolone;Placebo
47 Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis Recruiting NCT03945487 Phase 2
48 Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure Recruiting NCT03860155 Phase 1, Phase 2
49 Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure Not yet recruiting NCT03863002 Phase 1, Phase 2
50 Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure Withdrawn NCT01587222 Phase 2 Albumin;Midodrine;Octreotide

Search NIH Clinical Center for Hepatorenal Syndrome

Cochrane evidence based reviews: hepatorenal syndrome

Sources

Genetic Tests for Hepatorenal Syndrome

About this section
Sources

Anatomical Context for Hepatorenal Syndrome

About this section

MalaCards organs/tissues related to Hepatorenal Syndrome:

42
Liver, Kidney, Heart, Bone, Testes, Skin, Bone Marrow
Sources

Publications for Hepatorenal Syndrome

About this section

Articles related to Hepatorenal Syndrome:

(show top 50) (show all 746)
# Title Authors Year
1
Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. ( 30223273 )
2019
2
Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence. ( 30474439 )
2019
3
Terlipressin-Induced Peripheral Cyanosis in a Patient with Liver Cirrhosis and Hepatorenal Syndrome. ( 30600312 )
2019
4
Clinical utility of urinary neutrophil gelatinase-associated lipocalin and serum cystatin C in a cohort of liver cirrhosis patients with renal dysfunction: a challenge in the diagnosis of hepatorenal syndrome. ( 30601335 )
2019
5
Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome. ( 30606404 )
2019
6
Evaluation of the criteria of hepatorenal syndrome type of acute kidney injury in patients with cirrhosis admitted to ICU. ( 30621473 )
2019
7
Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. ( 30684079 )
2019
8
The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. ( 30724682 )
2019
9
Role of Probiotic Mixture with and Without Green Tea Extract in Prevention of Hepatorenal Syndrome in Rat Model. ( 30796765 )
2019
10
Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome. ( 30887050 )
2019
11
Hepatorenal Syndrome. ( 30996046 )
2019
12
Vasoconstrictors in hepatorenal syndrome - A critical review. ( 31023616 )
2019
13
Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. ( 31065370 )
2019
14
High versus low mean arterial pressures in hepatorenal syndrome: A randomized controlled pilot trial. ( 31096099 )
2019
15
Hepatorenal syndrome. ( 30213943 )
2018
16
A systematic review and meta-analysis of treatment for hepatorenal syndrome with traditional Chinese medicine. ( 30225390 )
2018
17
Noradrenaline for Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure: Hope Remains! ( 30229972 )
2018
18
Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study. ( 30271187 )
2018
19
Author Correction: Hepatorenal syndrome. ( 30323303 )
2018
20
Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. ( 30597709 )
2018
21
New Developments in Hepatorenal Syndrome. ( 28602971 )
2018
22
Management of ascites and hepatorenal syndrome. ( 28836115 )
2018
23
Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials. ( 28924736 )
2018
24
Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. ( 28991106 )
2018
25
Noradrenaline as an alternative medical treatment to terlipressin in the management of hepatorenal syndrome type 1. ( 29054321 )
2018
26
Hepatorenal syndrome: the clinical impact of vasoactive therapy. ( 29258378 )
2018
27
Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study. ( 29303765 )
2018
28
Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. ( 29391267 )
2018
29
Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. ( 29422242 )
2018
30
Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis. ( 29432366 )
2018
31
Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial. ( 29469046 )
2018
32
Development of an automated phenotyping algorithm for hepatorenal syndrome. ( 29530803 )
2018
33
Predictors of Response to Terlipressin in Hepatorenal Syndrome. ( 29551736 )
2018
34
Disruption of Renal Arginine Metabolism Promotes Kidney Injury in Hepatorenal Syndrome in Mice. ( 29631342 )
2018
35
A novel scoring model for predicting mortality risk in patients with cirrhosis and hepatorenal syndrome. ( 29634664 )
2018
36
Oxidative stress, NOx/l-arginine ratio and glutathione/glutathione S-transferase ratio as predictors of 'sterile inflammation' in patients with alcoholic cirrhosis and hepatorenal syndrome type II. ( 29658815 )
2018
37
Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. ( 29668606 )
2018
38
When Should We Stop Treatment With Terlipressin and Albumin for Patients With Hepatorenal Syndrome? ( 29684461 )
2018
39
Hepatorenal syndrome in the era of acute kidney injury. ( 29845739 )
2018
40
Response to Terlipressin in Hepatorenal Syndrome: Predict to Prognosticate! ( 29914639 )
2018
41
Clinical Outcomes after Liver Transplantation for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. ( 29992152 )
2018
42
Hepatorenal Syndrome: Physiology, Diagnosis and Management. ( 30087522 )
2018
43
High expression of type I inositol 1,4,5-trisphosphate receptor in the kidney of rats with hepatorenal syndrome. ( 30090007 )
2018
44
Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. ( 30178092 )
2018
45
Hepatorenal syndrome. ( 30213935 )
2018
46
Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial. ( 31097245 )
2018
47
A Case of Hepatorenal Syndrome and Abdominal Compartment Syndrome with High Renal Congestion. ( 28919595 )
2017
48
Progressive liver failure post acute hepatitis A, over a three-month period, resulting in hepatorenal syndrome and death. ( 27247182 )
2017
49
Influence of hepatorenal syndrome on outcome of living donor liver transplantation: A single-center experience in 357 patients. ( 27323334 )
2017
50
Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome. ( 27464593 )
2017
Sources

Variations for Hepatorenal Syndrome

About this section
Sources

Expression for Hepatorenal Syndrome

About this section
Search GEO for disease gene expression data for Hepatorenal Syndrome.
Sources

Pathways for Hepatorenal Syndrome

About this section

Pathways related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
FOXA2 and FOXA3 transcription factor networks 1
10.9 ALB F2
2
Endothelin Pathways 1
10.69 EDN1 NPY
3
IL1 and megakaryocytes in obesity 1
10.35 F2 IL18
4
A-beta Pathways: Plaque Formation and APP Metabolism 66
9.98 ACE CST3
Sources

GO Terms for Hepatorenal Syndrome

About this section

Cellular components related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 ACE ALB CST3 EDN1 F2 IL18
2 extracellular space GO:0005615 9.28 ACE ALB CST3 EDN1 F2 IL18

Biological processes related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of proteolysis GO:0045861 9.48 CST3 F2
2 regulation of vasoconstriction GO:0019229 9.46 ACE EDN1
3 cellular protein metabolic process GO:0044267 9.46 ALB CST3 F2 NPPA
4 positive regulation of heart rate GO:0010460 9.43 EDN1 NPPA
5 regulation of blood vessel size GO:0050880 9.4 EDN1 NPPA
6 response to muscle stretch GO:0035994 9.37 EDN1 NPPA
7 regulation of signaling receptor activity GO:0010469 9.35 EDN1 F2 IL18 NPPA NPY
8 amyloid-beta metabolic process GO:0050435 9.32 ACE REN
9 angiotensin maturation GO:0002003 9.26 ACE REN
10 regulation of blood pressure GO:0008217 9.02 ACE EDN1 NPPA NPY REN

Molecular functions related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.16 NPPA NPY
2 hormone activity GO:0005179 9.13 EDN1 NPPA NPY
3 signaling receptor binding GO:0005102 9.02 EDN1 F2 NPPA NPY REN
Sources

Sources for Hepatorenal Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....